Wockhardt (WOCKPHARMA) Q4 24/25 earnings summary

Executive summary

• Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025.

• Unmodified audit opinion received for both standalone and consolidated results.

• Re-appointment of Mr. Akhilesh Krishna Gupta as Independent Director for a second term and appointment of Mr. Virendra G. Bhatt as Secretarial Auditor for five years.

• Enabling proposal approved for raising funds via equity or convertible securities, subject to shareholder approval.

Financial highlights

• Standalone revenue from operations for FY25: Rs. 1,402 crore (up from Rs. 1,154 crore in FY24).

• Standalone net loss for FY25: Rs. 12 crore, significantly reduced from Rs. 422 crore loss in FY24.

• Consolidated revenue from operations for FY25: Rs. 3,012 crore (up from Rs. 2,798 crore in FY24).

• Consolidated net loss for FY25: Rs. 57 crore, improved from Rs. 472 crore loss in FY24.

• Q4 FY25 standalone net profit: Rs. 40 crore, compared to a net loss of Rs. 126 crore in Q4 FY24.

Outlook and guidance

• Board approved enabling resolution for potential capital raising to support future growth, subject to shareholder and regulatory approvals.